Preferential therapy for osteoarthritis by cord blood MSCs through regulation of chondrogenic cytokines

Wen Cheng Lo, Wei Hong Chen, Tzu Chieh Lin, Shiaw Min Hwang, Rong Zeng, Wei Che Hsu, Yu Ming Chiang, Ming Che Liu, David F. Williams, Win Ping Deng

研究成果: 雜誌貢獻文章

17 引文 (Scopus)

摘要

Osteoarthritis (OA) is a common rheumatic disease associated with imbalanced cartilage homeostasis which could be corrected by mesenchymal stem cells (MSCs) therapy. However, MSCs from different origins might exhibit distinct differentiation capacities. This study was undertaken to compare the therapeutic efficacies between MSCs from cord blood (CB-MSCs) and bone marrow (BM-MSCs) on OA treatment. The surface phenotypes and multipotent capacities of CB-MSCs and BM-MSCs were first characterized. The coculture commitment system was subsequently utilized for comparing the patterned molecules in stage-specific chondrogenesis of committed MSCs. For examining the therapeutic efficacies, committed CB-MSCs and BM-MSCs were encapsulated in neo-cartilage and subjected into pro-inflammatory cytokine environment. Finally, chondrogenic and inflammatory cytokine profiles in committed MSCs were evaluated. CB-MSCs and BM-MSCs were both negative for hematopoietic markers and positive for adhesion and mesenchymal cell markers. The CB-MSCs showed a markedly higher chondrogenic potential and relatively lower osteogenic and adipogenic capacities than BM-MSCs. During chondrogenesis, the committed CB-MSCs also showed significant increases in cell proliferation, adhesion molecules, signaling molecules, and chondrogenic-specific gene expressions in acoculture system. For the therapeutic efficacies, the committed CB-MSCs could strongly recover the pro-inflammatory cytokines diminished-Col II and proteoglycan expressions in a3D arthritic model. The IL-10, ICAM-1 and TGF-β1 were also up-regulated in committed CB-MSCs analyzed by using cytokine profiling. Our data demonstrate that CB-MSCs possess specific advantages in cartilage regeneration over BM-MSCs. The CB-MSCs showed a better therapeutic potential that can contribute to advanced cell-based transplantation for clinical OA therapy.
原文英語
頁(從 - 到)4739-4748
頁數10
期刊Biomaterials
34
發行號20
DOIs
出版狀態已發佈 - 七月 2013

指紋

Stem cells
Mesenchymal Stromal Cells
Fetal Blood
Osteoarthritis
Blood
Cytokines
Therapeutics
Cartilage
Chondrogenesis
Molecules
Adhesion
Cell Transplantation
Cell proliferation
Cell Adhesion Molecules

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

引用此文

Preferential therapy for osteoarthritis by cord blood MSCs through regulation of chondrogenic cytokines. / Lo, Wen Cheng; Chen, Wei Hong; Lin, Tzu Chieh; Hwang, Shiaw Min; Zeng, Rong; Hsu, Wei Che; Chiang, Yu Ming; Liu, Ming Che; Williams, David F.; Deng, Win Ping.

於: Biomaterials, 卷 34, 編號 20, 07.2013, p. 4739-4748.

研究成果: 雜誌貢獻文章

Lo, Wen Cheng ; Chen, Wei Hong ; Lin, Tzu Chieh ; Hwang, Shiaw Min ; Zeng, Rong ; Hsu, Wei Che ; Chiang, Yu Ming ; Liu, Ming Che ; Williams, David F. ; Deng, Win Ping. / Preferential therapy for osteoarthritis by cord blood MSCs through regulation of chondrogenic cytokines. 於: Biomaterials. 2013 ; 卷 34, 編號 20. 頁 4739-4748.
@article{38260f54c44e4ab2b27160573fe4c45f,
title = "Preferential therapy for osteoarthritis by cord blood MSCs through regulation of chondrogenic cytokines",
abstract = "Osteoarthritis (OA) is a common rheumatic disease associated with imbalanced cartilage homeostasis which could be corrected by mesenchymal stem cells (MSCs) therapy. However, MSCs from different origins might exhibit distinct differentiation capacities. This study was undertaken to compare the therapeutic efficacies between MSCs from cord blood (CB-MSCs) and bone marrow (BM-MSCs) on OA treatment. The surface phenotypes and multipotent capacities of CB-MSCs and BM-MSCs were first characterized. The coculture commitment system was subsequently utilized for comparing the patterned molecules in stage-specific chondrogenesis of committed MSCs. For examining the therapeutic efficacies, committed CB-MSCs and BM-MSCs were encapsulated in neo-cartilage and subjected into pro-inflammatory cytokine environment. Finally, chondrogenic and inflammatory cytokine profiles in committed MSCs were evaluated. CB-MSCs and BM-MSCs were both negative for hematopoietic markers and positive for adhesion and mesenchymal cell markers. The CB-MSCs showed a markedly higher chondrogenic potential and relatively lower osteogenic and adipogenic capacities than BM-MSCs. During chondrogenesis, the committed CB-MSCs also showed significant increases in cell proliferation, adhesion molecules, signaling molecules, and chondrogenic-specific gene expressions in acoculture system. For the therapeutic efficacies, the committed CB-MSCs could strongly recover the pro-inflammatory cytokines diminished-Col II and proteoglycan expressions in a3D arthritic model. The IL-10, ICAM-1 and TGF-β1 were also up-regulated in committed CB-MSCs analyzed by using cytokine profiling. Our data demonstrate that CB-MSCs possess specific advantages in cartilage regeneration over BM-MSCs. The CB-MSCs showed a better therapeutic potential that can contribute to advanced cell-based transplantation for clinical OA therapy.",
keywords = "Bone marrow mesenchymal stem cells, Chondrogenesis, Commitment, Cord blood mesenchymal stem cells, Osteoarthritis",
author = "Lo, {Wen Cheng} and Chen, {Wei Hong} and Lin, {Tzu Chieh} and Hwang, {Shiaw Min} and Rong Zeng and Hsu, {Wei Che} and Chiang, {Yu Ming} and Liu, {Ming Che} and Williams, {David F.} and Deng, {Win Ping}",
year = "2013",
month = "7",
doi = "10.1016/j.biomaterials.2013.03.016",
language = "English",
volume = "34",
pages = "4739--4748",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",
number = "20",

}

TY - JOUR

T1 - Preferential therapy for osteoarthritis by cord blood MSCs through regulation of chondrogenic cytokines

AU - Lo, Wen Cheng

AU - Chen, Wei Hong

AU - Lin, Tzu Chieh

AU - Hwang, Shiaw Min

AU - Zeng, Rong

AU - Hsu, Wei Che

AU - Chiang, Yu Ming

AU - Liu, Ming Che

AU - Williams, David F.

AU - Deng, Win Ping

PY - 2013/7

Y1 - 2013/7

N2 - Osteoarthritis (OA) is a common rheumatic disease associated with imbalanced cartilage homeostasis which could be corrected by mesenchymal stem cells (MSCs) therapy. However, MSCs from different origins might exhibit distinct differentiation capacities. This study was undertaken to compare the therapeutic efficacies between MSCs from cord blood (CB-MSCs) and bone marrow (BM-MSCs) on OA treatment. The surface phenotypes and multipotent capacities of CB-MSCs and BM-MSCs were first characterized. The coculture commitment system was subsequently utilized for comparing the patterned molecules in stage-specific chondrogenesis of committed MSCs. For examining the therapeutic efficacies, committed CB-MSCs and BM-MSCs were encapsulated in neo-cartilage and subjected into pro-inflammatory cytokine environment. Finally, chondrogenic and inflammatory cytokine profiles in committed MSCs were evaluated. CB-MSCs and BM-MSCs were both negative for hematopoietic markers and positive for adhesion and mesenchymal cell markers. The CB-MSCs showed a markedly higher chondrogenic potential and relatively lower osteogenic and adipogenic capacities than BM-MSCs. During chondrogenesis, the committed CB-MSCs also showed significant increases in cell proliferation, adhesion molecules, signaling molecules, and chondrogenic-specific gene expressions in acoculture system. For the therapeutic efficacies, the committed CB-MSCs could strongly recover the pro-inflammatory cytokines diminished-Col II and proteoglycan expressions in a3D arthritic model. The IL-10, ICAM-1 and TGF-β1 were also up-regulated in committed CB-MSCs analyzed by using cytokine profiling. Our data demonstrate that CB-MSCs possess specific advantages in cartilage regeneration over BM-MSCs. The CB-MSCs showed a better therapeutic potential that can contribute to advanced cell-based transplantation for clinical OA therapy.

AB - Osteoarthritis (OA) is a common rheumatic disease associated with imbalanced cartilage homeostasis which could be corrected by mesenchymal stem cells (MSCs) therapy. However, MSCs from different origins might exhibit distinct differentiation capacities. This study was undertaken to compare the therapeutic efficacies between MSCs from cord blood (CB-MSCs) and bone marrow (BM-MSCs) on OA treatment. The surface phenotypes and multipotent capacities of CB-MSCs and BM-MSCs were first characterized. The coculture commitment system was subsequently utilized for comparing the patterned molecules in stage-specific chondrogenesis of committed MSCs. For examining the therapeutic efficacies, committed CB-MSCs and BM-MSCs were encapsulated in neo-cartilage and subjected into pro-inflammatory cytokine environment. Finally, chondrogenic and inflammatory cytokine profiles in committed MSCs were evaluated. CB-MSCs and BM-MSCs were both negative for hematopoietic markers and positive for adhesion and mesenchymal cell markers. The CB-MSCs showed a markedly higher chondrogenic potential and relatively lower osteogenic and adipogenic capacities than BM-MSCs. During chondrogenesis, the committed CB-MSCs also showed significant increases in cell proliferation, adhesion molecules, signaling molecules, and chondrogenic-specific gene expressions in acoculture system. For the therapeutic efficacies, the committed CB-MSCs could strongly recover the pro-inflammatory cytokines diminished-Col II and proteoglycan expressions in a3D arthritic model. The IL-10, ICAM-1 and TGF-β1 were also up-regulated in committed CB-MSCs analyzed by using cytokine profiling. Our data demonstrate that CB-MSCs possess specific advantages in cartilage regeneration over BM-MSCs. The CB-MSCs showed a better therapeutic potential that can contribute to advanced cell-based transplantation for clinical OA therapy.

KW - Bone marrow mesenchymal stem cells

KW - Chondrogenesis

KW - Commitment

KW - Cord blood mesenchymal stem cells

KW - Osteoarthritis

UR - http://www.scopus.com/inward/record.url?scp=84876076947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876076947&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.03.016

DO - 10.1016/j.biomaterials.2013.03.016

M3 - Article

C2 - 23557858

AN - SCOPUS:84876076947

VL - 34

SP - 4739

EP - 4748

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 20

ER -